Other research analysts also recently issued reports about the company. Berenberg Bank reissued a buy rating and issued a GBX 1,760 ($24.32) price objective on shares of GlaxoSmithKline in a research note on Wednesday, December 13th. UBS set a GBX 1,550 ($21.41) price objective on GlaxoSmithKline and gave the company a buy rating in a research note on Wednesday, December 13th. Jefferies Group reissued a buy rating and issued a GBX 1,500 ($20.72) price objective on shares of GlaxoSmithKline in a research note on Tuesday, January 16th. Liberum Capital reissued a buy rating and issued a GBX 1,760 ($24.32) price objective on shares of GlaxoSmithKline in a research note on Monday, January 15th. Finally, Goldman Sachs set a GBX 1,775 ($24.52) price objective on GlaxoSmithKline and gave the company a buy rating in a research note on Friday, December 1st. One analyst has rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the company. The company has an average rating of Hold and a consensus price target of GBX 1,529.55 ($21.13).
GlaxoSmithKline (GSK) traded up GBX 41.80 ($0.58) during midday trading on Friday, reaching GBX 1,315.60 ($18.18). The company had a trading volume of 23,227,458 shares, compared to its average volume of 9,120,000. GlaxoSmithKline has a 1 year low of GBX 1,235.20 ($17.07) and a 1 year high of GBX 1,724.50 ($23.83). The firm has a market cap of $65,630.00 and a P/E ratio of 2,482.26.
In other GlaxoSmithKline news, insider Sir Roy Anderson acquired 562 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was purchased at an average cost of GBX 1,278 ($17.66) per share, with a total value of £7,182.36 ($9,923.13). Also, insider Victoria Whyte sold 5,199 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of GBX 1,295 ($17.89), for a total value of £67,327.05 ($93,018.86). Over the last ninety days, insiders acquired 591 shares of company stock valued at $756,678 and sold 23,765 shares valued at $31,152,709.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.